This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Blood levels of homocysteine are elevated in Alzheimer's disease (AD), and hyperhomocysteinemia may contribute to disease pathophysiology by vascular and direct neurotoxic mechanisms. Homocysteine levels can be reduced by administration of high dose supplements of folic acid and vitamins B6 and B12. We propose a multicenter, randomized, controlled clinical trial to determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will slow the rate of cognitive decline in subjects with AD. This will be a parallel design study, including two groups of unequal size: 60% of subjects will receive daily high-dose supplements (folic acid 5mg, vitamin B6 25mg, vitamin B12 1 mg), and 40% will receive identical placebo; the duration of treatment will be 18 months. The primary outcome measure will be the longitudinal decline in the ADAScog. To power the trial to detect a 25% reduction in rate of ADAScog decline (80% power, alpha=0.05, drop-out estimate 20%, drop-in estimate 10%), we will enroll a total of 400 subjects. This trial was developed by Dr. Aisen, and is being directed by Dr. Aisen and his group at Georgetown. The pilot study of the treatment regimen was also led by Dr. Aisen, and conducted at the Georgetown GCRC plus three other sites. The present trial is funded by NIA through the Alzheimer's Disease Cooperative Study (ADCS, Leon Thal, Director, Paul Aisen, Associate Director), and utilizes the ADCS Data Center at UCSD, and ADCS sites around the U.S.
SPECIFIC AIMS : Primary: 1. Determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will slow the rate of cognitive decline in subjects with AD Secondary: 2. Determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will slow the rate of clinical decline, as measured by the time to reach clinically significant end-points, in subjects with AD 3. Determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will favorably influence measures of behavior, activities of daily living, global status, and quality of life in subjects with AD 4. Examine the influence of apolipoprotein E and methylenetetrahydrofolate reductase (MTHFR) genotype on homocysteine reduction in subjects with AD 5. Determine the safety and tolerability of long-term treatment of AD subjects with high-dose supplements. Hypothesis: Blood levels of homocysteine are elevated in Alzheimer's disease (AD), and hyperhomocysteinemia may contribute to disease pathophysiology by vascular and direct neurotoxic mechanisms. Homocysteine levels can be reduced by administration of high dose supplements of folic acid and vitamins B6 and B12. We are conducting a multicenter, randomized, controlled clinical trial to determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will slow the rate of cognitive decline in subjects with AD.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR020359-02
Application #
7376133
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2005-12-01
Project End
2006-11-30
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
2
Fiscal Year
2006
Total Cost
$20,651
Indirect Cost
Name
Children's Research Institute
Department
Type
DUNS #
143983562
City
Washington
State
DC
Country
United States
Zip Code
20010
Sady, Maegan D; Vaughan, Christopher G; Gioia, Gerard A (2018) Measuring Dynamic Symptom Response in Concussion: Children's Exertional Effects Rating Scale. J Head Trauma Rehabil :
Mullins, Tanya L Kowalczyk; Li, Su X; Bethel, James et al. (2018) Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy. J Clin Virol 102:7-11
Kahn, Jessica A; Xu, Jiahong; Kapogiannis, Bill G et al. (2017) Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay. J Acquir Immune Defic Syndr 75:241-245
Smits, Anne; van den Anker, John N; Allegaert, Karel (2017) Clinical pharmacology of analgosedatives in neonates: ways to improve their safe and effective use. J Pharm Pharmacol 69:350-360
Newport, Elissa L; Landau, Barbara; Seydell-Greenwald, Anna et al. (2017) Revisiting Lenneberg's Hypotheses About Early Developmental Plasticity: Language Organization After Left-Hemisphere Perinatal Stroke. Biolinguistics (Nicos) 11:407-422
Gioia, Gerard A (2016) Medical-School Partnership in Guiding Return to School Following Mild Traumatic Brain Injury in Youth. J Child Neurol 31:93-108
Terwilliger, Virginia K; Pratson, Lincoln; Vaughan, Christopher G et al. (2016) Additional Post-Concussion Impact Exposure May Affect Recovery in Adolescent Athletes. J Neurotrauma 33:761-5
Ruan, Alexandra; Tobin, Nicole H; Mulligan, Kathleen et al. (2016) Brief Report: Macrophage Activation in HIV-Infected Adolescent Males Contributes to Differential Bone Loss by Sex: Adolescent Trials Network Study 021. J Acquir Immune Defic Syndr 72:372-5
Orrock, Janet E; Panchapakesan, Karuna; Vezina, Gilbert et al. (2016) Association of brain injury and neonatal cytokine response during therapeutic hypothermia in newborns with hypoxic-ischemic encephalopathy. Pediatr Res 79:742-7
Sepeta, Leigh N; Berl, Madison M; Wilke, Marko et al. (2016) Age-dependent mesial temporal lobe lateralization in language fMRI. Epilepsia 57:122-30

Showing the most recent 10 out of 203 publications